Innovation Saving Lives

We are a biotechnology company with a proprietary epigenetic biomarker discovery platform, EpiSwitch™, based on the latest advances in regulatory genome architecture and its link to clinical outcomes and patient stratification.

EpiSwitch™ biomarkers based on chromosomal conformation signatures are a critical cog in personalised medicine.

Technology to select the right drug at the right dose at the right time for the right patient.

EpiSwitch™ captures the heterogeneity of the environment on the genome.

Recent Publications on Chromosome Conformation Signatures

Generative modeling of multi-mapping reads with mHi-C advances analysis of Hi-C studies.

Zheng, Y., et. al.,

InTAD: chromosome conformation guided analysis of enhancer target genes.

Okonechnikov, K., et. al.,
BMC Bioinformatics

MACPET: model-based analysis for ChIA-PET.

Vardaxis, I, et. al.,

Non-coding RNAs and chromatin domains.

Yamamoto, T., et. al.,
Curr. Opin. Cell Biol.

Spatial Principles of Chromatin Architecture Associated With Organ-Specific Gene Regulation

Chapski, DK., et. al.,
Front. Cardiovasc. Med.